Skip to main content
Premium Trial:

Request an Annual Quote

Enpicom, MiLaboratories Partner on Immune Repertoire Sequencing Software Integration

NEW YORK – Enpicom and MiLaboratories on Tuesday announced a strategic partnership to integrate MiLaboratories' MiXCR immune repertoire sequencing software into Enpicom's ImmunoGenomix (IGX) bioinformatics platform.

Integrating the MiLaboratories software "really contributes to the adoption of professional repertoire sequencing data management and analysis," Enpicom CEO Jos Lunenberg said in a statement. "We look forward to jointly start serving customers shortly and further expanding our collaboration with MiLaboratories in the near future."

"With this integration, we intend to expand [MiXCR's] usability with embedding management, annotation, visualization, and sharing capabilities into repertoire sequencing analysis workflows," MiLaboratories CEO Yuri Nikolsky said in a statement. "This enables customers to obtain more insights from their next-generation sequencing data, adding significant value in drug discovery, development, and academic environments."

Financial and other terms of the deal were not disclosed.

Based in s’Hertogenbosch, the Netherlands, Enpicom offers the IGX platform to manage, store, analyze, visualize, and interpret T and B cell repertoire sequencing data.

Solana Beach, California-based MiLaboratories offers a human T cell receptor profiling kit, immune cell profiling services, and software tools and algorithms to analyze immune cell profiles.

In December 2019, Enpicom partnered with Cytura Therapeutics to develop an NGS-based cancer diagnostic quantifying mutations that cause genome instability.

And in August of last year, MiLaboratories collaborated with MIODx on immune repertoire profiling in the US and Europe.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more